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Objective: Our study aims to systematically assess and report the methodological quality used in 52 
epidemiological systematic reviews (SRs) and meta-analysis (MA) of pathogen 53 
genotypes/genogroups. 54 
Study Design and Setting: Nine electronic databases and manual search of reference lists were 55 
used to identify relevant studies. The method types w re divided into three groups: 1) with 56 
weighted pooling analysis (which we call MA); 2) unweighted analysis of the study-level 57 
measures, which we call summary statistics; and 3) without any data pooling (which we call SR 58 
only). Characteristics were evaluated using AMSTAR, P ISMA, and ROBIS tool. The protocol 59 
was registered in PROSPERO with CRD42017078146. 60 
Results: Among 36 included articles, 5 (14%) studies conducted SR only, 16 (44%) performed 61 
MA, and 15 (42%) used summary statistics. The uni- a d multivariable linear regression of 62 
AMSTAR and PRISMA scores showed that MA had higher quality compared to those with 63 
summary statistics. The SR only and summary statistics groups had approximately equal scores 64 
among three scales of AMSTAR, PRISMA and ROBIS. The m thodological quality of 65 
epidemiological studies has improved from 1999 to 2017.   66 
Conclusion: Despite the frequent use of unweighted summary statistics, MA remains the most 67 
suitable method for reaching rational conclusions i epidemiological studies of pathogen 68 
genotypes/genogroups.  69 
Keywords: methodological quality, systematic review, summary statistics, meta-analysis, 70 
genotypes, genogroups. 71 
Words count of abstract: 200 words. 72 





Systematic review (SR) and meta-analysis (MA) have become cornerstones of evidence-based 77 
medicine, since they involve strategies to aggregate all relevant studies on a topic of interest [1]. 78 
They can provide robust inferences which help policymakers estimate benefits and risks of an 79 
intervention [2]. Currently, more than 10,000 MAs and qualitative SRs are published annually 80 
[3, 4]. However, substandard methodology and manipulation of statistical techniques in SR and 81 
MA are seldom considered [5]. 82 
Therefore, the Preferred Reporting Items for Systema ic Reviews and Meta-analyses (PRISMA) 83 
statement, a 27-item checklist and a four-phase flow diagram, was developed as a tool for 84 
critiquing and enhancing the reporting of SRs and MAs [6]. In addition, the Assessment of 85 
Multiple Systematic Reviews (AMSTAR) tool is a 11-item checklist for multiple SRs and MAs, 86 
and provides for vigorous assessment of methodology and research reliability [7]. PRISMA and 87 
AMSTAR have been used to evaluate the research methodology in multiple medical fields, 88 
including surgery, pulmonary disease, telerehabilittion, nursing, gastroenterology and 89 
hepatology [8-10].  90 
Due to the mounting number of epidemiological studies on genotypes or genogroups of 91 
pathogens, researchers and clinicians turn to SR and MA to keep up with the rising genomic 92 
knowledge [1]. However, there is a paucity of methodol gical investigations monitoring SR and 93 
MA [11]. In addition, there has been a call for appropriate assessment tools to examine potential 94 
bias in epidemiological studies [12]. Therefore, SR and MA of epidemiological genotypic studies 95 
should follow strict methodological appraisal to less n any probable bias.  When combining 96 
studies in meta-analysis, “an overall treatment effect is calculated as a weighted average of the 97 
individual summary statistics” [13].  Such weighting, based on each study’s sample size and 98 
variation, is crucial to obtain a reliable summary of the evidence.  However, in addition to those 99 
studies which do SR only (without any data pooling), several studies use simple summary 100 
statistics (e.g. unweighted mean) of the study-level m asures, instead of MA methods [14-16]. 101 
For instance, Ali et al. reported simple summary statistics (mean and standard eviation) of 102 
study-level prevalences of hepatitis B virus [14] (although the abstract mentions weighting, this 103 
is not substantiated in the methods, and the numerical esults, for example for the surgery 104 
studies, are unweighted).  Due to the large number of SRs using non-MA methods, our study 105 
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aimed to systematically assess and evaluate the methods used in data analysis of epidemiological 106 
SRs of pathogen genotypes/genogroups. 107 
 108 
Materials and methods 109 
Search strategy 110 
The protocol was designed and registered in the interna ional prospective register of systematic 111 
reviews (PROSPERO) with ID number CRD42017078146. In September 2017, a systematic 112 
search was conducted in nine electronic databases: PubMed, Scopus, ISI (Web of Science), 113 
WHO Global Health Library, Virtual Health Library, Google Scholar, New York Academy of 114 
Medicine Grey Literature Report (NYAM) and System for Information on Grey Literature in 115 
Europe (SIGLE). The details of search terms used in each database are found in Supplemental 116 
Table S1. The search was performed by AMS and the references were stored using Endnote 117 
X7.0.1. We also performed a manual search in January 2018 to reach any possibly missed 118 
articles. Manual search was done by checking based on references of included articles, the 119 
related articles on PubMed search results and citation lists of included articles on Google Scholar 120 
[17].  121 
Selection criteria 122 
To be included in our study, the paper has to be either a SR or MA [18], which involved the 123 
prevalence or epidemiology of genotypes or genogroups of pathogens. No restriction was placed 124 
on publication date, language or disease area. A SR/MA article is defined as one or more of the 125 
following characteristics: (i) containing “systematic review” or “meta-analysis” on the title and 126 
abstract; (ii) containing PRISMA flow diagram; (iii) combining and summarizing all available 127 
research evidence from a systematic search fulfilling pre-determined criteria to answer a pre-128 
defined question [1, 19-21]. The reason of exclusion was due to two main causes: (i) content not 129 
satisfying criteria: the article is not a SR/MA and (ii) inappropriate study design, such as: 130 
abstract-only articles, theses, conferences, letters, commentaries or books. The first stage of the 131 
screening process included the identification of titles and abstracts by three independent 132 
reviewers (EA, MMH and AMS). In the second stage, relevant articles proceeded to full-text 133 
 6
evaluation; the consensus was reached among three authors (AH, AS and AMS), otherwise 134 
consulted by the senior author (NTH).  135 
Data extraction  136 
A template in Microsoft Excel was built for pilot extraction and training. Afterwards, three 137 
independent reviewers (MNY, AH and LT) extracted the data and disagreements were resolved 138 
by discussion between authors and senior author (NTH). Authors extracted characteristics that 139 
included name and country of first author, year of publication, number of authors, impact factor 140 
(IF) of journal, and method types. Three main method types were defined in our study: 1-MA, a 141 
study conducted weighted pooling analysis; 2-Summary statistics, which used unweighted 142 
analysis of the study-level measures; 3-SR only, which is a SR study without any data pooling. 143 
Items of the AMSTAR and PRISMA checklists were assembl d [22, 23]. The AMSTAR 144 
checklist is an 11-item list [7] and the PRISMA statement is a 27-item list [24]. Items of both 145 
tools were judged with; “Yes”, “No”, “Can’t Answer” or “Not Applicable” (NA) response which 146 
meet “fulfilled”, “not fulfilled”, and “not clear” respectively. Any disagreements were resolved 147 
by discussion between the authors. 148 
Quality assessment  149 
The AMSTAR checklist was used to assess the methodological quality meanwhile the PRISMA 150 
checklist was used to assess reporting quality of the included SRs and/or MAs [6, 7]. In addition, 151 
the risk of bias was evaluated by three independent reviewers (TLBN, EA and LT) using Risk Of 152 
Bias In Systematic reviews (ROBIS) tool [25]. We focused on rating phase 2 and phase 3 of 153 
ROBIS, which involved a total of five domains with 24 signaling questions (SQ) and one overall 154 
judgment regarding the risk of bias for each domain. Phase 2 assesses the level of bias based on 155 
four domains: (1) study eligibility criteria (SQ=5), (2) identification and selection of studies 156 
(SQ=5), (3) data collection and study appraisal (SQ=5) and (4) synthesis and findings (SQ=6). In 157 
phase 3, each reviewer made a judgment about the overall risk of bias (domain 5, SQ=3). In each 158 
domain, the summary risk of bias was rated as “low”, “high” or “unclear” through discussion by 159 
each reviewer in each included SR. Each SQ in each domain were answered as “Yes” = Good 160 
description/No bias, “No” = Bias, “Probably Yes”, “Probably No”, and “No Information”. The 161 
total score for ROBIS was developed by the number of “Yes” answers in each question of each 162 
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domain [26, 27]. To have the scoring comparability with all three scales, the scoring 163 
determination of AMSTAR, PRISMA and ROBIS was “Yes” = 1 and “No” = 0.  164 
Data analysis 165 
Statistical software R version 3.4.4 was used for data analysis. (http://www.r-project.org/). 166 
Firstly, the characteristics of included articles, including the three main methods (MA, summary 167 
statistics and SR only), number of authors, IF of the journal, year of publication, and region of 168 
the corresponding author, were summarized using frequency and percentage for categorical 169 
variables. Mean and standard deviation (SD) for numeric variable were calculated. Polychoric 170 
correlation was calculated between the AMSTAR, PRISMA and ROBIS scores. Correlation 171 
coefficients have a value ranging between -1 (perfect negative correlation) and +1 (perfect 172 
positive correlation). We refer to negative correlation when coefficient was < 0, and to positive 173 
correlation when it as was > 0 [28]. We used linear r gression model to evaluate the association 174 
between the articles' characteristics (IF of published journal, year of publication, region of 175 
corresponding author, number of authors, and study type) with AMSTAR, PRISMA, and ROBIS 176 
scores. Multivariable linear regression including all these covariates was then performed for each 177 
score to deal with potential confounders between thm. Results from the uni- and multivariable 178 
models were reported as mean difference (MD), 95% confidence interval (CI), and the 179 




Study identification 184 
Overall, we identified 3,543 potentially relevant reports by searching nine electronic databases 185 
and then removing 909 duplications using Endnote X7.0.1. After screening titles and abstracts of 186 
2,634 references and removing 2,537 irrelevant reports according to the exclusion criteria, 97 187 
articles were included for full-text screening. Of these, 68 articles were excluded due to 188 
exclusion criteria. From manual search of cited litera ure, 7 articles were added. Hence we 189 
included 36 studies in our analysis. The flow diagram of the review selection process is shown in 190 
Figure 1. 191 
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Characteristics of included articles 192 
Major characteristics of the included articles, according to the method types (SR only, summary 193 
statistics and MA), are shown in Table 1. Of these 36 articles, 5 (14%) were SR only [29-33], 194 
15 (42%) used summary statistics [14, 16, 34-46], and 16 (44%) used MA methods [47-62]. 195 
Details of all the included articles are listed in Supplemental Table S2. The publication years 196 
ranged from 1999 to 2017. Analysis over time demonstrates that, on all three measures, the 197 
methodological quality of epidemiological studies has improved from 1999 to 2017, in which 198 
AMSTAR is the lowest compared with PRISMA and ROBIS ( upplemental Figure S1). 199 
Overall, there is an average of 6.8 authors per paper nd the mean IF is 3 ± 2.3  (Table 1, 200 
Supplemental Figure S2). The most frequent region is Asia (39%), followed by Europe (25%), 201 
North America (14%), with others contributing 22%. 202 
In detail, the total AMSTAR, PRISMA and ROBIS scores of all included articles, according to 203 
the number of authors, are presented in Supplemental Figure S3. Most studies have fewer than 204 
10 authors. The PRISMA and ROBIS scores, but not AMSTAR, tend to increase with the 205 
number of authors. The detailed scores by region are shown in Supplemental Figure S4. 206 
Articles from North America overall has the highest mean score, on all three scales. Studies from 207 
Europe have the lowest mean AMSTAR score while those from Asia have the lowest mean 208 
PRISMA and ROBIS scores. 209 
Variables associated with AMSTAR scores 210 
Supplemental Table S3 presents the reporting quality of individual AMSTAR items. The 211 
highest scoring items include two items, such as providing a priori design (item 1, 97.2%) and a 212 
comprehensive literature search performed (item 3, 88.9%). Some other items are poorly 213 
reported, including: providing a list of included and excluded studies (item 5, 36.1%), the 214 
scientific quality of the included studies (item 7, 38.9%), and an assessment of publication bias 215 
(item 10, 33.3%). In general, the AMSTAR score (mean ± SD) is 6.7 ± 2.7 out of a maximum of 216 
11 (61% of items adequately reported, on average). 217 
Results of uni- and multivariable linear regression with AMSTAR outcome are presented in 218 
Table 2. From 1999 to 2017, there is an increase of 0.33 points per year in AMSTAR scores 219 
(95% CI: 0.11 to 0.55, p=0.004). The summary statistics (non-MA) articles are associated with a 220 
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decrease in 2.65 AMSTAR points (95% CI: -4.37 to -0.92, p = 0.004) in univariable analysis and 221 
3.04 points (95% CI: -4.97 to -1.10, p = 0.003) in multivariable analysis, compared with MA 222 
articles. Similarly, the SR only articles have 3.51 fewer AMSTAR points (95% CI: -5.97 to -223 
1.05, p = 0.006) in univariable analysis and 3.69 fewer points (95% CI: -6.68 to -0.70, p = 0.017) 224 
in multivariable analysis, compared to MA articles.  225 
Variables associated with PRISMA scores 226 
Supplemental Table S4 shows the proportion of MAs that adequately reported each PRISMA 227 
item. Most are reported well, such as justifying a rationale for the study (item 3, 97.2%), 228 
identifying the objectives of the study (item 4, 94.4%), stating the eligibility criteria (item 6, 229 
91.7%), providing a summary of the evidence including the main findings (item 24, 91.7%) and 230 
providing conclusions (item 26, 88.9%). Some other it ms are poorly reported, such as 231 
describing whether a protocol and/or registration (registration number) of the review was 232 
available (item 5, 25%), describing the assessment risk of bias across studies in the methods 233 
(item 15, 25%), stating risk of bias within studies n the results (item 19, 22.2%), and stating the 234 
funding (item 27, 36.1%). In general, the PRISMA score is 17.4 ± 4.6 out of a maximum of 27 235 
(64% of items adequately reported, on average). 236 
Uni- and multivariable regression results from PRISMA outcomes are shown in Table 3. From 237 
1999 to 2017, there is an increase of 0.52 points per year in PRISMA scores (95% CI: 0.14 to 238 
0.90, p= 0.009) in univariable analysis. Additionally, in multivariable analysis, there is an 239 
increase of 0.22 points in PRISMA score per additional author (95% CI: 0.02 to 0.43, p=0.035). 240 
Compared with MA articles, the summary statistics articles have 6.01 fewer points on average 241 
(95% CI: -8.60 to -3.43, p<0.001) in univariable analysis, and 5.75 fewer (95% CI: -8.94 to -242 
2.56, p = 0.001) in multivariable analysis. Similarly, the SR only articles have 6.61 fewer points 243 
(95% CI: -10.29 to -2.93, p = 0.001) than MA articles in univariable analysis.  244 
Association between AMSTAR, PRISMA, ROBIS scores 245 
Polychoric correlation between each pair of AMSTAR, PRISMA and ROBIS scores is shown in 246 
Supplemental Figure S5. All three pairwise correlation coefficients are more than 0.4, 247 
suggesting a positive correlation among three scale of AMSTAR, PRISMA and ROBIS scores. 248 
The highest is 0.77 between ROBIS and PRISMA, then 0.61 between AMSTAR and PRISMA, 249 
and finally by 0.53 between ROBIS and AMSTAR.  250 
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Figure 2 presents that MA consistently has highest score meanwhile the summary statistics 251 
(non-MA) and SR only studies has lower and approximately equal scores on all three scales of 252 
AMSTAR, PRISMA and ROBIS. 253 
Quality assessment based on ROBIS scores 254 
Results of uni- and multivariable linear regression with ROBIS scores are shown in Table 4. 255 
Also, the ROBIS score is 13.9 ± 4.6 (range 2-24) out of 24 SQs. The ROBIS assessment to 256 
evaluate the risk of bias within a SR according to five domains is presented in Figure 3. With 257 
regard to domain 1, which assesses any concerns regardin  specification of study eligibility 258 
criteria, 17 studies (47.2%) achieve a low risk of bias rating [30, 31, 35-38, 41, 48, 49, 51, 52, 259 
54, 56, 57, 59, 60, 62]. In domain 2, identification and selection of studies, 20 studies (55.5%) 260 
have low risk of bias rating. In domain 3, which assesses methods used to collect data and 261 
appraise studies, 8 studies achieve a low risk of bias rating (22.2%) [32, 35, 49, 50, 52, 57-59]. 262 
With regard to domain 4, which assesses concerns regarding the synthesis and findings, 10 263 
articles have low risk of bias (27.7%) [29, 31, 35,8  40, 46, 48, 52, 57, 58]. The final section 264 
(domain 5) provides a rating for the overall risk of bias of each SR: 20 are achieved a low rating 265 
(55.5%) [29, 31, 32, 35-37, 41-43, 45, 46, 48, 50, 52, 54-59], 8 are rated high (22.2%) [30, 34, 266 
38, 51, 53, 60-62] and 8 are rated as unclear (22.2%) [14, 16, 33, 39, 40, 44, 47, 49].  267 
 268 
Discussion 269 
In this study, we describe the methodological reporting quality of methods used in 270 
epidemiological studies of pathogen genotypes/genogroups. Nearly half of the investigated SR 271 
articles employed simple descriptive analysis of study-level measures, rather than weighted 272 
meta-analysis methods. These articles had significatly lower reporting quality score (AMSTAR 273 
and PRISMA) compared to those using MA. Strong positive correlations between AMSTAR, 274 
PRISMA and ROBIS were also noted, in which, ROBIS is considerably correlated with 275 
PRISMA (0.77), followed by AMSTAR highly correlated with PRISMA (0.61), and finally 276 
AMSTAR moderately correlated with ROBIS (0.53), whic  indicates higher quality of 277 
AMSTAR is associated with higher score of ROBIS (lower bias). Similarly, Buhn et al. showed 278 
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that the percentage of “yes” scores of ROBIS ratings was strongly correlated with the AMSTAR 279 
ratings (correlation coefficient of 0.76) [27].  280 
Besides the traditional SR and MA studies, we found a  increase over time (1999-2017) in the 281 
use of unweighted summary statistics of study-level m asures.  We also found an increase in 282 
study quality over time. This finding is consistent wi h comparable studies of SRs and MAs in 283 
other fields such as gastroenterology, hepatology, cardiovascular diseases, vascular surgery and 284 
genetic association [63-66]. We did not find a signif cant correlation between the journal’s IF 285 
and methodological quality of the SRs or MAs. Compared to the study by Ruano et al. where 286 
they analyzed 164 reviews, our study only included 36 studies, so the inability to identify an 287 
association may have been due to lack of power. This finding was in accordance with a report by 288 
Minelli et al. on the quality of MAs of genetic association studies [66]. Moreover, we also found 289 
a significant, but small positive correlation between PRISMA outcome score and the number of 290 
authors.  291 
A limitation of our study was that it focused on the reporting quality of methodological details, 292 
which may not adequately reflect the quality of the underlying work done, as reported by 293 
Zavitsanos et al. in the field of urolithiasis [67]. In other words, a well-designed and well-294 
conducted MA can be considered at high risk of biasif the description does not do justice to the 295 
methods used. Also, although ROBIS tool is considere  as effective and reliable in measuring 296 
the overall risk of bias of SRs instead of only methodological quality, it requires greater expertise 297 
in reviewing due to more complex SQs than AMSTAR [27]. In addition, the use of scoring 298 
summary should be taken into account [68].    299 
In this study, we utilized the PRISMA, AMSTAR and ROBIS checklist. There has been a critical 300 
appraisal of AMSTAR [69]. Therefore, there are certain limitations of the assessment 301 
instruments used in this paper that merits careful consideration. We recommend researchers in 302 
this field to adhere to certain guidelines or checklists, such as PRISMA or AMSTAR when 303 
conducting and reporting their research. This will ensure proper quality standard for all 304 
epidemiological articles of pathogen genotypes or geno roups. We found that the 305 
methodological qualities of studies employing MA method are better compared to the ones that 306 
employ SR only or summary statistics. We are uncertain about the reason behind this finding. 307 




In summary, we found the methodological quality of articles using MA methods to be superior to 311 
that of SR only studies and to those using unweightd summary statistics, despite the growing 312 
frequency of the latter. There was an increase over time in the methodological quality of 313 
epidemiological studies of pathogen genotypes or geno roups, while still calling for further 314 
improvement. Authors, journal editors and readers should be attentive to the methodological 315 
quality of SRs and help maintain MA methods as one f the most effective tools in rationally 316 




 References 320 
1. Uman LS. Systematic reviews and meta-analyses. Journal of the Canadian Academy of 321 
Child and Adolescent Psychiatry 2011; 20: 57-59.  322 
2. Impellizzeri FM, Bizzini M. Systematic review and meta‐analysis: A primer. 323 
International Journal of Sports Physical Therapy 2012; 7: 493.  324 
3. Sackmann EK, Fulton AL, Beebe DJ. The present and future role of microfluidics in 325 
biomedical research. Nature 2014; 507: 181.  326 
4. Hung BT, Long NP, Hung le P, et al. Research trends in evidence-based medicine: a 327 
joinpoint regression analysis of more than 50 years of publication data. PLoS One 2015; 10: 328 
e0121054. DOI: 10.1371/journal.pone.0121054 329 
5. Alliger GM, Tannenbaum SI, Bennett W, Traver H, Shotland A. A meta‐analysis of the 330 
relations among training criteria. Personnel Psychology 1997; 50: 341-358.  331 
6. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic 332 
reviews and meta-analyses: the PRISMA statement. International Journal of Surgery 2010; 8: 333 
336-341.  334 
7. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool 335 
to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 336 
2007; 7: 10.  337 
8. Adie S, Ma D, Harris IA, Naylor JM, Craig JC. Quality of conduct and reporting of meta-338 
analyses of surgical interventions. Annals of surgery 2015; 261: 685-694.  339 
9. Ho RS, Wu X, Yuan J, et al. Methodological quality of meta-analyses on treatments for 340 
chronic obstructive pulmonary disease: a cross-sectional study using the AMSTAR (Assessing 341 
the Methodological Quality of Systematic Reviews) tool. NPJ primary care respiratory medicine 342 
2015; 25: 14102.  343 
10. Rogante M, Kairy D, Giacomozzi C, Grigioni M. A quality assessment of systematic 344 
reviews on telerehabilitation: what does the evidence tell us? Annali dell'Istituto superiore di 345 
sanita 2015; 51: 11-18.  346 
11. Dickersin K. Systematic reviews in epidemiology: why are we so far behind? 347 
International Journal of Epidemiology 2002; 31: 6-12.  348 
12. Sanderson S, Tatt ID, Higgins J. Tools for asses ing quality and susceptibility to bias in 349 
observational studies in epidemiology: a systematic review and annotated bibliography. 350 
International Journal of Epidemiology 2007; 36: 666-676.  351 
13. Akobeng AK. Understanding systematic reviews and meta-analysis. Archives of Disease 352 
in Childhood 2005; 90: 845-848. DOI: 10.1136/adc.2004.058230 353 
14. Ali M, Idrees M, Ali L, et al. Hepatitis B virus in Pakistan: a systematic review of 354 
prevalence, risk factors, awareness status and genotypes. Virology Journal 2011; 8: 102. DOI: 355 
10.1186/1743-422X-8-102 356 
15. Hoa Tran TN, Trainor E, Nakagomi T, Cunliffe NA, Nakagomi O. Molecular 357 
epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: global 358 
distribution of genogroups, genotypes and GII.4 variants. Journal of Clinical Virology 2013; 56: 359 
185-193. DOI: 10.1016/j.jcv.2012.11.011 360 
16. Attaullah S, Khan S, Ali I. Hepatitis C virus genotypes in Pakistan: a systemic review. 361 
Virology Journal 2011; 8: 433. DOI: 10.1186/1743-422X-8-433 362 
 14 
17. Vassar M, Atakpo P, Kash MJ. Manual search approaches used by systematic reviewers 363 
in dermatology. Journal of the Medical Library Association 2016; 104: 302-304. DOI: 364 
10.3163/1536-5050.104.4.009 365 
18. Moher D, Altman DG, Liberati A, Tetzlaff J. PRISMA statement. Epidemiology 2011; 366 
22: 128; author reply 128. DOI: 10.1097/EDE.0b013e3181fe7825 367 
19. Higgin J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Wiley 368 
2011. 369 
20. Giang HTN, Ahmed AM, Fala RY, et al. Methodological steps used by authors of 370 
systematic reviews and meta-analyses of clinical tri ls: a cross-sectional study. BMC Medical 371 
Research Methodology 2019; 19: 164-164. DOI: 10.1186/s12874-019-0780-2 372 
21. Swartz MK. The PRISMA statement: a guideline for systematic reviews and meta-373 
analyses. Journal of Pediatric Health Care 2011; 25: 1-2. DOI: 10.1016/j.pedhc.2010.09.006 374 
22. Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to 375 
assess the methodological quality of systematic reviews. Journal of Clinical Epidemiology 2009; 376 
62: 1013-1020.  377 
23. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for 378 
systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009; 6: 379 
e1000097.  380 
24. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic 381 
reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and 382 
elaboration. BMJ 2009; 339: b2700. DOI: 10.1136/bmj.b2700 383 
25. Whiting P, Savović J, Higgins JPT, et al. ROBIS: A new tool to assess risk of bias in 384 
systematic reviews was developed. Journal of Clinical Epidemiology 2016; 69: 225-234. DOI: 385 
10.1016/j.jclinepi.2015.06.005 386 
26. Banzi R, Cinquini M, Gonzalez-Lorenzo M, Pecorar  V, Capobussi M, Minozzi S. 387 
Quality assessment versus risk of bias in systematic reviews: AMSTAR and ROBIS had similar 388 
reliability but differed in their construct and applicability. Journal of Clinical Epidemiology 389 
2018; 99: 24-32. DOI: 10.1016/j.jclinepi.2018.02.024 390 
27. Bühn S, Mathes T, Prengel P, et al. The risk of bias in systematic reviews tool showed 391 
fair reliability and good construct validity. Journal of Clinical Epidemiology 2017; 91: 121-128. 392 
DOI: 10.1016/j.jclinepi.2017.06.019 393 
28. Pearson K. Mathematical contributions to the theory of evolution. VII. On the correlation 394 
of characters not quantitatively measurable. Philosophical Transactions of the Royal Society of 395 
London. Series A, Containing Papers of a Mathematical or Physical Character 1900; 195: 1-47. 396 
DOI: doi:10.1098/rsta.1900.0022 397 
29. Mitra AK. Hepatitis C-related hepatocellular cacinoma: prevalence around the world, 398 
factors interacting, and role of genotypes. Epidemiologic Reviews 1999; 21: 180-187.  399 
30. Riddell MA, Rota JS, Rota PA. Review of the temporal and geographical distribution of 400 
measles virus genotypes in the prevaccine and postvaccine eras. Virology Journal 2005; 2: 87. 401 
DOI: 10.1186/1743-422X-2-87 402 
31. Hosseini E, Poursina F, de Wiele TV, Safaei HG,Adibi P. Helicobacter pylori in Iran: A 403 
systematic review on the association of genotypes and g stroduodenal diseases. Journal of 404 
Research in Medical Sciences 2012; 17: 280-292.  405 
32. Reyna-Figueroa J, Sanchez-Uribe E, Esteves-Jaramillo A, Hernandez-Hernandez Ldel C, 406 
Richardson V. Diarrheal disease caused by rotavirus in epidemic outbreaks. Revista 407 
Panamericana de Salud Pública 2012; 31: 142-147.  408 
 15 
33. Fernandez C, Jaimes J, Ortiz MC, Ramirez JD. Host and Toxoplasma gondii genetic and 409 
non-genetic factors influencing the development of ocular toxoplasmosis: A systematic review. 410 
Infection, Genetics and Evolution 2016; 44: 199-209. DOI: 10.1016/j.meegid.2016.06.053 411 
34. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus 412 
epidemiology in Asia, Australia and Egypt. Liver International 2011; 31 Suppl 2: 61-80. DOI: 413 
10.1111/j.1478-3231.2011.02540.x 414 
35. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of 415 
hepatitis C virus infection: new estimates of age-sp cific antibody to HCV seroprevalence. 416 
Hepatology 2013; 57: 1333-1342. DOI: 10.1002/hep.26141 417 
36. Kershenobich D, Razavi HA, Sanchez-Avila JF, et al. Trends and projections of hepatitis 418 
C virus epidemiology in Latin America. Liver International 2011; 31 Suppl 2: 18-29. DOI: 419 
10.1111/j.1478-3231.2011.02538.x 420 
37. Ezzikouri S, Pineau P, Benjelloun S. Hepatitis C virus infection in the Maghreb region. 421 
Journal of Medical Virology 2013; 85: 1542-1549. DOI: 10.1002/jmv.23643 422 
38. Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review 423 
of prevalence, genotypes and risk factors. World Journal of Gastroenterology 2009; 15: 5647-424 
5653.  425 
39. Zhu CT, Dong CL. Characteristics of general distribution of hepatitis B virus genotypes 426 
in China. Hepatobiliary & Pancreatic Diseases International 2009; 8: 397-401.  427 
40. Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbonye AK, Wabwire FM. 428 
Epidemiology of HPV genotypes in Uganda and the rolof the current preventive vaccines: A 429 
systematic review. Infectious Agents and Cancer 2011; 6: 11. DOI: 10.1186/1750-9378-6-11 430 
41. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus 431 
epidemiology in Europe, Canada and Israel. Liver International 2011; 31 Suppl 2: 30-60. DOI: 432 
10.1111/j.1478-3231.2011.02539.x 433 
42. Than VT, Kim W. Prevalence of rotavirus genotypes in South Korea in 1989-2009: 434 
implications for a nationwide rotavirus vaccine program. Korean Journal of Pediatrics 2013; 56: 435 
465-473. DOI: 10.3345/kjp.2013.56.11.465 436 
43. Cucher MA, Macchiaroli N, Baldi G, et al. Cystic echinococcosis in South America: 437 
systematic review of species and genotypes of Echino occus granulosus sensu lato in humans 438 
and natural domestic hosts. Tropical Medicine & International Health 2016; 21: 166-175. DOI: 439 
10.1111/tmi.12647 440 
44. Petruzziello A, Marigliano S, Loquercio G, Cozzlino A, Cacciapuoti C. Global 441 
epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of 442 
hepatitis C virus genotypes. World Journal of Gastroenterology 2016; 22: 7824-7840. DOI: 443 
10.3748/wjg.v22.i34.7824 444 
45. Umer M, Iqbal M. Hepatitis C virus prevalence and genotype distribution in Pakistan: 445 
Comprehensive review of recent data. World Journal of Gastroenterology 2016; 22: 1684-1700. 446 
DOI: 10.3748/wjg.v22.i4.1684 447 
46. Chaichan P, Mercier A, Galal L, et al. Geographical distribution of Toxoplasma gondii 448 
genotypes in Asia: A link with neighboring continents. Infection, Genetics and Evolution 2017; 449 
53: 227-238. DOI: 10.1016/j.meegid.2017.06.002 450 
47. Harfouche M, Chemaitelly, H., Mahmud, S., Chaabna, K., Kouyoumjian, S., Al Kanaani, 451 
Z., & Abu-raddad, L. . Epidemiology of hepatitis C virus among hemodialysis patients in the 452 
Middle East and North Africa: Systematic syntheses, meta-analyses, and meta-regressions. 453 
Epidemiology and Infection 2017; 145: 3243-3263. DOI: 10.1017/S0950268817002242 454 
 16 
48. Chemaitelly H, Chaabna K, Abu-Raddad LJ. The Epidemiology of Hepatitis C Virus in 455 
the Fertile Crescent: Systematic Review and Meta-Anlysis. PLoS One 2015; 10: e0135281. 456 
DOI: 10.1371/journal.pone.0135281 457 
49. Tricco AC, Ng CH, Gilca V, Anonychuk A, Pham B, erliner S. Canadian oncogenic 458 
human papillomavirus cervical infection prevalence: systematic review and meta-analysis. BMC 459 
Infectious Diseases 2011; 11: 235. DOI: 10.1186/1471-2334-11-235 460 
50. Peng R-R, Li H-M, Chang H, Li J-H, Wang AL, Chen X-S. Prevalence and genotype 461 
distribution of cervical human papillomavirus infection among female sex workers in Asia: a 462 
systematic literature review and meta-analysis. Sexual Health 2012; 9: 113-119. DOI: 463 
https://doi.org/10.1071/SH11066 464 
51. Stam AJ, Nijhuis M, van den Bergh WM, Wensing AM. Differential genotypic evolution 465 
of HIV-1 quasispecies in cerebrospinal fluid and plasma: a systematic review. AIDS Reviews 466 
2013; 15: 152-161.  467 
52. Ogembo RK, Gona PN, Seymour AJ, et al. Prevalence of Human Papillomavirus 468 
Genotypes among African Women with Normal Cervical Cytology and Neoplasia: A Systematic 469 
Review and Meta-Analysis. PLoS One 2015; 10: e0122488. DOI: 10.1371/journal.pone.0122488 470 
53. de Almeida Júnior JN, Hennequin C. Invasive Trichosporon Infection: a Systematic 471 
Review on a Re-emerging Fungal Pathogen. Frontiers in Microbiology 2016; 7: 1629-1629. 472 
DOI: 10.3389/fmicb.2016.01629 473 
54. Malary M, Moosazadeh M, Hamzehgardeshi Z, Afshari M, Moghaddasifar I, 474 
Afsharimoghaddam A. The Prevalence of Cervical Human P pillomavirus Infection and the 475 
Most At-risk Genotypes Among Iranian Healthy Women: A Systematic Review and Meta-476 
analysis. International Journal of Preventive Medicine 2016; 7: 70-70. DOI: 10.4103/2008-477 
7802.181756 478 
55. Mancusi RL, Andreoni M, d'Angela D, Sarrecchia C, Spandonaro F. Epidemiological 479 
burden estimates for pathologies with a nonconstant risk: an application to HCV in Italy 480 
according to age, Metavir score, and genotype: A systematic review and meta-analysis. Medicine 481 
(Baltimore) 2016; 95: e5143. DOI: 10.1097/MD.0000000000005143 482 
56. Menon S, Wusiman A, Boily MC, et al. Epidemiology of HPV Genotypes among HIV 483 
Positive Women in Kenya: A Systematic Review and Meta-Analysis. PLoS One 2016; 11: 484 
e0163965-e0163965. DOI: 10.1371/journal.pone.0163965 485 
57. Nibali L, Di Iorio A, Onabolu O, Lin GH. Periodntal infectogenomics: systematic 486 
review of associations between host genetic variants d subgingival microbial detection. 487 
Journal of Clinical Periodontology 2016; 43: 889-900. DOI: 10.1111/jcpe.12600 488 
58. Sadeghi F, Salehi-Vaziri M, Almasi-Hashiani A, Gholami-Fesharaki M, Pakzad R, 489 
Alavian SM. Prevalence of Hepatitis C Virus Genotypes Among Patients in Countries of the 490 
Eastern Mediterranean Regional Office of WHO (EMRO): A Systematic Review and Meta-491 
Analysis. Hepatitis Monthly 2016; 16: e35558-e35558. DOI: 10.5812/hepatmon.35558 492 
59. Badparva E, Ezatpour B, Mahmoudvand H, Behzadifar M, Behzadifar M, Kheirandish F. 493 
Prevalence and Genotype Analysis of Blastocystis hominis in Iran: A Systematic Review and 494 
Meta-Analysis. Archives of Clinical Infectious Disease 2017; 12: e36648. DOI: 495 
10.5812/archcid.36648 496 
60. Bissett SL, Godi A, Jit M, Beddows S. Seropositivity to non-vaccine incorporated 497 
genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and 498 
meta-analysis. Vaccine 2017; 35: 3922-3929. DOI: 10.1016/j.vaccine.2017.06.028 499 
 17 
61. Mahmud S, Al-Kanaani Z, Chemaitelly H, Chaabna K, Kouyoumjian SP, Abu-Raddad 500 
LJ. Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and 501 
patterns. Journal of Medical Virology 2018; 90: 131-141. DOI: 10.1002/jmv.24921 502 
62. Zhang Y, Chen LM, He M. Hepatitis C Virus in mainl nd China with an emphasis on 503 
genotype and subtype distribution. Virology Journal 2017; 14: 41. DOI: 10.1186/s12985-017-504 
0710-z 505 
63. Liu P, Qiu Y, Qian Y, et al. Quality of meta-analyses in major leading gastroenterology 506 
and hepatology journals: A systematic review. Journal of Gastroenterology and Hepatology 507 
2017; 32: 39-44. DOI: 10.1111/jgh.13591 508 
64. Palma S, Delgado-Rodriguez M. Assessment of publication bias in meta-analyses of 509 
cardiovascular diseases. Journal of Epidemiology and Community Health 2005; 59: 864-869. 510 
DOI: 10.1136/jech.2005.033027 511 
65. Tan WK, Wigley J, Shantikumar S. The reporting quality of systematic reviews and 512 
meta-analyses in vascular surgery needs improvement: a systematic review. International 513 
Journal of Surgery 2014; 12: 1262-1265. DOI: 10.1016/j.ijsu.2014.10.05 514 
66. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. The quality of meta-515 
analyses of genetic association studies: a review with recommendations. American Journal of 516 
Epidemiology 2009; 170: 1333-1343. DOI: 10.1093/aje/kwp350 517 
67. Zavitsanos PJ, Bird VG, Mince KA, Neuberger MM, Dahm P. Low methodological and 518 
reporting quality of randomized, controlled trials of devices to treat urolithiasis. The Journal of 519 
Urology 2014; 191: 988-993. DOI: 10.1016/j.juro.2013.10.067 520 
68. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials 521 
for meta-analysis. JAMA 1999; 282: 1054-1060. DOI: 10.1001/jama.282.11.1054 522 
69. Faggion CM, Jr. Critical appraisal of AMSTAR: challenges, limitations, and potential 523 
solutions from the perspective of an assessor. BMC Medical Research Methodology 2015; 15: 524 




List of figures and tables 528 
In manuscript 529 
Figure 1. Flow diagram of the systematic search, review search nd identification. 530 
Figure 2. Comparison between MA, summary statistics and SR only articles according to 531 
AMSTAR, PRISMA and ROBIS score. 532 
Figure 3. Risk of bias of all included articles according to ROBIS tool. 533 
 534 
Table 1. Principal characteristics of included articles. 535 
Table 2. Association of factors with AMSTAR scores. 536 
Table 3. Association of factors with PRISMA scores. 537 
Table 4. Association of factors with ROBIS scores. 538 
539 
 19 
Supplementary files 540 
Supplemental Figure S1. The AMSTAR, PRISMA and ROBIS score based on year of 541 
publication. 542 
Supplemental Figure S2. The AMSTAR, PRISMA and ROBIS score based on impact factor of 543 
published journals. 544 
Supplemental Figure S3. The AMSTAR, PRISMA and ROBIS score based on number of 545 
authors. 546 
Supplemental Figure S4. The AMSTAR, PRISMA and ROBIS score based on the region of 547 
study. 548 
Supplemental Figure S5. Polychoric correlation to compare scales between each pair of 549 
AMSTAR, PRISMA and ROBIS score. 550 
 551 
Supplemental Table S1. Detailed search strategy for each database search. 552 
Supplemental Table S2. Summary of included articles. 553 
Supplemental Table S3. Distribution of individual questions in AMSTAR for all included 554 
studies. 555 











Summary statistics  
(N=15) SR only (N=5) 
Number of authors 6.8 (6.7) 5.3 (2.0) 9.3 (9.7) 3.6 (1.7) 
Impact Factor 3.0 (2.3) 2.5 (1.1) 3.5 (3.2) 3.1 (2.6) 
Year     
- 1999 1 (2.8%) 0 (0.0%) 0 (0.0%) 1 (20.0%) 
- 2005 1 (2.8%) 0 (0.0%) 0 (0.0%) 1 (20.0%) 
- 2009 2 (5.6%) 0 (0.0%) 2 (13.3%) 0 (0.0%) 
- 2011 8 (22.2%) 2 (12.5%) 6 (40.0%) 0 (0.0%) 
- 2012 2 (5.6%) 0 (0.0%) 0 (0.0%) 2 (40.0%) 
- 2013 4 (11.1%) 1 (6.2%) 3 (20.0%) 0 (0.0%) 
- 2015 2 (5.6%) 2 (12.5%) 0 (0.0%) 0 (0.0%) 
- 2016 10 (27.8%) 6 (37.5%) 3 (20.0%) 1 (20.0%) 
- 2017 6 (16.7%) 5 (31.2%) 1 (6.7%) 0 (0.0%) 
Region     
- Asia 14 (38.9%) 8 (50.0%) 6 (40.0%) 0 (0.0%) 
- Europe 9 (25.0%) 5 (31.2%) 3 (20.0%) 1 (20.0%) 
- North America 5 (13.9%) 2 (12.5%) 1 (6.7%) 2 (40.0%) 
- Others 8 (22.2%) 1 (6.2%) 5 (33.3%) 2 (40.0%) 
The summary statistics are absolute count (%) for categorical variables and mean (SD) for 561 




Table 2. Association of factors with AMSTAR scores. 565 
 Univariable analysis Multivariable analysis 
Characteristics Coefficient 95% CI p Coefficient 95% CI p 
Impact Factor 0 -0.41 to 0.41 0.999 0.11 -0.28 to 0.50 0.568 
Year 0.33 0.11 to 0.55 0.004 0.19 -0.08 to 0.47 0.164 
Region:       
- Asia reference  reference reference  reference 
- Europe 0.09 -2.32 to 2.49 0.94 -0.16 -2.20 to 1.88 0.871 
- North America 0.04 -2.89 to 2.98 0.97 1.43 -1.72 to 4.59 0.36 
- Others 1.52 -0.98 to 4.02 0.23 2.98 0.76 to 5.20 0.01 
Number of authors 0.01 -0.13 to 0.15 0.85 0.02 -0.11 to 0.15 0.747 
Method type:       
- MA reference  reference  R f rencrreference  reference 
- Summary statistics -2.65 -4.37 to -0.92 0.004 -3.04 -4.97 to -1.10 0.003 




Table 3. Association of factors with PRISMA scores. 568 
 Univariable analysis Multivariable analysis 
Characteristics Coefficient  95% CI p Coefficient 95% CI p 
Impact Factor -0.11 -0.80 to 0.57 0.741 -0.03 -0.67 to 0.62 0.936 
Year 0.52 0.14 to 0.90 0.009 0.31 -0.15 to 0.77 0.176 
Region:       
- Asia reference  reference reference  reference 
- Europe 1.42 -2.67 to 5.51 0.49 0.13 -3.24 to 3.49 0.938 
- North America 0.44 -4.55 to 5.43 0.86 2.91 -2.30 to 8.12 0.262 
- Others -1.73 -5.98 to 2.51 0.41 -0.25 -3.90 to 3.40 0.89 
Number of authors 0.10 -0.13 to 0.34 0.38 0.22 0.02 to 0.43 0.035 
Method type:       
- MA reference  reference reference  reference 
- Summary statistics -6.01 -8.60 to -3.43 <0.001 -5.75 -8.94 to -2.56 0.001 
- SR only -6.61 -10.29 to -2.93 0.001 -4.89 -9.82 to 0.05 0.052 
569 
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Table 4. Association of factors with ROBIS scores. 570 
 Univariable analysis Multivariable analysis 
Characteristics Coefficient 95% CI p Coefficient 95% CI p 
Impact Factor 0.20 -0.49 to 0.90 0.564 -0.14 -0.98 to 0.70 0.737 
Year 0.10 -0.32 to 0.52 0.632 -0.01 -0.61 to 0.57 0.962 
Region:       
- Asia reference  reference reference  reference 
- Europe 1.46 -2.53 to 5.45 0.462 1.31 -3.04 to 5.66 0.542 
- North America 3.37 -1.50 to 8.24 0.168 5.49 -1.25 to 12.22 0.106 
- Others -1.55 -5.70 to 2.59 0.451 -0.18 -4.90 to 4.54 0.938 
Number of authors 0.093 -0.15 to 0.33 0.437 0.14 -0.13 to 0.41 0.288 
Method type:       
- MA reference  reference reference  reference 
- Summary statistics -2.88 -6.14 to 0.37 0.081 -2.83 -6.95 to 1.30 0.171 
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